Jun 19: Drug maker Zydus Cadila on Tuesday said that it has received tentative approval from the USFDA to market its Tadalafil Tablets USP, 2.5 mg, 5 mg, 10 mg and 20 mg.
According to the company, the product is used to treat erectile dysfunction (impotence) and symptoms of benign prostatic hypertrophy (enlarged prostate). It will be manufactured at the group’s manufacturing facility at Moraiya, Ahmedabad, the company said.
Based in Ahmedabad, the Pankaj R Patel promoted Zydus Cadila Group is a research driven drug maker that discovers, develops, manufactures and markets a broad range of healthcare therapies.
The group now has more than 195 approvals and has so far filed over 330 ANDAs since the commencement of the filing process in FY 2003-04.
Shares of Cadila Healthcare, the group’s listed entity, were trading at Rs 403.05, up 0.62% from the previous closing of Rs 400.55, on BSE at 12.40 pm today.